RemeGen (HKG:9995, SHA:688331) booked 328 million yuan in attributable profit for the first quarter of 2026, swinging from a loss of 254.1 million yuan a year earlier, according to a Hong Kong bourse filing Tuesday.
The biopharmaceutical company's Hong Kong shares were down 2% in late morning trade Wednesday.
Earnings per share were 0.58 yuan, compared with a loss of 0.46 year in the prior year period.
Operating revenue jumped 25% year on year to 656.2 million yuan, figures showed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments